Anebulo Pharmaceuticals, Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.anebulo.com

Market Cap $38.64M
PE -5
Debt $NaN
Cash $1.40M
EV $NaN
FCF $NaN

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$7.92M
EBIT	-$8.18M
ROE	-417%
ROA	-331%
Equity	$1.90M
Growth Stability	1
PE	-4.88
PB	20.35
Price/Cash	0.04
Equity CAGR	-47%
Earnings Growth YoY	-11%

Earnings Growth QoQ	63%
Equity CAGR 5Y	-47%
Equity CAGR 3Y	-53%
Market Cap	$38.64M
Assets	$2.47M
Cash	$1.40M
Shares Outstanding	25.93M
Shares Growth 3y	5%
Equity Growth QoQ	-50%
Equity Growth YoY	-77%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company. It is developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.

SEC Filings

Direct access to Anebulo Pharmaceuticals, Inc. (ANEB) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-K Jun 30
- 10-Q Mar 31
2023
- 10-Q Dec 31
- 10-Q Sep 30
- 10-K Jun 30
- 10-Q Mar 31
2022
- 10-Q Dec 31
- 10-Q Sep 30
- 10-K Jun 30
- 10-Q Mar 31

Sector Comparison

How does Anebulo Pharmaceuticals, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Anebulo Pharmaceuticals, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Anebulo Pharmaceuticals, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Anebulo Pharmaceuticals, Inc..

Years

Calculation mode

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
DCF		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Value	$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	06/2021	06/2022	06/2023	06/2024	TTM
Net Margins	-	-	-	-	-
ROA	-17%	-44%	-101%	-204%	-331%
ROE	-180%	-45%	-111%	-215%	-417%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	06/2021	06/2022	06/2023	06/2024	TTM
Debt over FCF	-	-	-	-	-
Debt over Equity	-	-	-	-	-
Growth Stability	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	06/2021	06/2022	06/2023	06/2024	CAGR 5Y
Revenue YoY growth	-	-	-	-	-
Earnings YoY growth	-	-82%	72%	-30%	-
Equity YoY growth	-	-30%	-30%	-64%	-47%
FCF YoY growth	-	-	-	-	-